SLN
Silence Therapeutics plc
NASDAQ · GBHealthcareBiotechnology
$10.49-0.10%
Price as of Jul 20, 2026
SLN financials
Silence Therapeutics plc financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $559.0K | $43.3M | $25.4M | $17.7M |
| Cost of revenue | $215.0K | $11.8M | $10.3M | $11.0M |
| Gross profit | $344.0K | $31.4M | $15.1M | $6.7M |
| Operating expenses | $90.1M | $94.8M | $64.7M | $56.4M |
| Operating income | -$89.8M | -$63.3M | -$49.6M | -$49.8M |
| Net income | -$88.6M | -$45.3M | -$43.3M | -$41.0M |
| EBITDA | -$88.0M | -$49.0M | -$49.8M | -$39.9M |
| Basic EPS | $-1.89 | $-2.37 | $-3.48 | $-3.78 |
| Diluted EPS | $-1.89 | $-2.37 | $-3.48 | $-3.78 |
| Balance sheet | ||||
| Cash & equivalents | $11.3M | $97.0M | $68.8M | $54.8M |
| Total assets | $131.4M | $161.9M | $119.4M | $107.5M |
| Total liabilities | $69.1M | $54.8M | $97.5M | $85.4M |
| Stockholders’ equity | $62.3M | $107.1M | $22.0M | $22.1M |
| Total debt | $160.0K | $93.5K | $346.0K | $446.0K |
| Net debt | -$11.1M | -$96.9M | -$68.4M | -$54.4M |
| Cash flow | ||||
| Operating cash flow | -$62.3M | -$54.1M | -$39.4M | -$57.0M |
| Capital expenditure | -$55.0K | -$168.6K | -$45.0K | -$545.0K |
| Free cash flow | -$62.3M | -$54.2M | -$39.4M | -$57.6M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |